NCT07074418RecruitingPhase 4
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 - EMPA [10-20]
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The proximal tubule remains the main site for sodium reabsorption in patients with advanced renal failure. The investigators therefore hypothesize that SGLT2i should still exert a significant natriuretic effect in patients with eGFR below 20 ml/min/1.73m2, and therefore should still decrease proteinuria with a potential renal protective effect.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 30 Jun 2025
- Start date
- 25 Aug 2026
- Primary completion date
- May 2028
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Chronic kidney disease
- NCT number
- NCT07074418
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 34
- From 25 Aug 2026 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- participation in another clinical study with an investigational medicinal product (IMP) administered during the month before screening,
Other illness
- any medical condition that, in the opinion of the investigator makes the participant not suitable for inclusion,
- history of ketoacidosis in the past while on empagliflozin or any other SGLT2i class drugs,
- known hypersensitivity or intolerance to empagliflozin or any of the excipients of the product,
Other
- judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements,
- no social insurance,
- unwilling to give informed consent,
- vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak French).
Who the study is looking for
- type 2 diabetics,
- age between 18 and 80 years,
- RAS blockade at maximal tolerated dosage for 1 month,
- eGFR (CKD-EPI) between 10 and 20 ml/min/1.73m2,
- UACR \> 300mg/g creatinine and UPCR \> 500mg/g creatinine,
- office systolic blood pressure \> 110 mmHg,
- stable dosage of antihypertensive drugs and diuretics for 1 month.
- for women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Nice - Hôpital Pasteur 2 Coordinator of this site? Confirm its status | Nice | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.